Surgery Partners, Inc. (SGRY) Misses Q2 EPS by 1c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Surgery Partners, Inc. Announces Second Quarter 2022 Results
August 2, 2022 7:30 AM EDTRevenue increased 13.3% from the prior year period to $615.4 million Days adjusted same-facility revenues increased 6.9% from the prior year period Net loss attributable to common stockholders was $18.4 million Adjusted EBITDA increased 13.4% over the prior year period to $86.1 million, inclusive of a $0.1 million benefit from the recognition of CARES Act grantsExcluding CARES Act grants, Adjusted EBITDA increased 17.8% over the prior year period, with Adjusted EBITDA margins of 14.0% Reaffirm projected 2022 Adjusted EBITDA in the range of $375 million to $385 million and 2022 revenue in the range... More
